Author: Joel Hanhart (Israel)
Co-authors: Rony Wiener, Hashem Totah, Evgeny Gelman, Yishay Weill, Adi Abulafia, David Zadok
Purpose
To assess the impact of COVID-19 related delay in intravitreal injection timing on macular structure and visual acuity among patients treated for neovascular age-related macular degeneration (nvAMD).
Setting/Venue
This retrospective study included consecutive patients who received appointments with one retina specialist at the Shaare Zedek Medical Center, a tertiary ophthalmology center, for anti-VEGF injection from March to April 2020 – the "first wave of COVID-19".
Methods
We reviewed demographic and clinical data as well as macular OCT images of 34 patients (48 eyes , group A) who departed from their original injection schedule during the first wave of COVID-19 and compared them to 46 patients (71 eyes, group B) who, during the same period, followed the original treatment plan. Functional worsening was defined as a loss of at least 0.1 in decimal visual acuity. Anatomic worsening was defined as new or worsening of subretinal/intraretinal fluids or new hemorrhage.
Results
The planned interval period between intravitreal injections were 5.7±2.7 and 5.5±2.4 weeks in group A and group B, respectively (p=0.60). The mean actual interval period between intravitreal injections was 13.6±6.8 (delay of 7.9±5.2 weeks;) and 5.3±2.4 weeks (0 weeks delay) in group A and group B, respectively (p <0.001). The best corrected visual acuity worsened in 23 eyes (47.9%) and in 6 eyes (8.5%) in group A and group B, respectively (OR 9.97, p <0.001). Anatomic features indicating worsening of the disease were detected in 31 eyes (64.6%) and 16 eyes (22.5%) in group A and in group B, respectively (OR=5.73, p <0.001). A new macular hemorrhage was observed in 4 eyes (8.3%) in group A, while no new bleeding was observed in group B (p=0.09).
Conlusions
In nvAMD patients, delay in retinal care during the Covid-19 restrictions period results in negative short-term outcomes, including macular bleeding.
Financial Disclosure
N/A
Comments
-